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novel analogues were synthesized by our research group. All synthesized chemicals were dissolved and diluted using dimethyl sulfoxide (DMSO) except special announcement.
Plasmids construction of NAMPT wild-type and mutants
cDNA sequence of human NAMPT was amplified by PCR from pGex-6p-3-hNAMPT plasmid (kindly gift from Dr. Shui-Qing Ye in University of Missouri) using the following primers: forward, 5'-GGACATATGATGAATCCTGCGGCAGAAGC-3'; and reverse, 5'-AATCTCGA -GGTAATGATGTGCTGCTTCCAGTTC-3'. The PCR products were digested and cloned into pET21a+ vector using NdeI and XhoI restriction enzyme. Point mutation was introduced by quick change site-directed mutagenesis method 1 using the constructed pET21a+-hNAMPT plasmid as a template. Primers used for mutagenesis were as follows: H191A forward, 5'-CTGGAATACAAGTTAGCTGATTTTGGCTACAGAG-3', and reverse, 5'-CTCTGTAGCCAAAATCAGCTAACTTGTATTCCAG-3'; A244S forward:
5'-GCTATTCTG -TTCCATCAGCAGAACACAG-3', and reverse:
5'-GTACTGTGTTCTGCTAGTGGAACAGA -ATAGCC-3'; S275A forward:
5'-CATCAGTGCCTGTAGCTGTGGTCAGCG 3', and reverse:
5'-CGCTGACCACAGCTACAGGCACTGATG-3'; I309Y forward 5'-CACAGGCACCACTATA -CATCAGACCTGATTCTGG-3', and reverse:
5'-CCAGAATCAGGTCTGATGTATAGTGGTG -CCTGTG-3'; R311M forward:
5'-GCACCACTAATAATCATGCCTGATTCTGGAAAC-3', and reverse:
5'-GTTTCCAGAATCAGGCATGATTATTAGTGGTGC-3'. All the mutations were validated by DNA sequencing.
Protein expression and purification
Proteins were expressed and purified by our previous methods 2, 3 . His-tagged NAMPT wild-type, NAMPT mutants and NMNAT1 (mouse NMNAT1-pET28a+ plasmid is a kind gift from Dr. Shin-ichiro Imai in Washington University) were expressed in BL21-CondonPlus (DE3)-RIL cells (Stratagene) at 28 °C, in 2×YT media containing 100 μg/ml kanamycin and 37 μg/ml chloramphenicol, and then purified with nickel-nitrilotriacetic acid resin (Qiagen).
The purity of the protein was more than 90% determined by SDS-PAGE and Coomassie Blue (Tiangen, China) staining and further by western blot analysis (Fig. S1 ).
High throughput screening (HTS)
HTS was performed using our previously reported method 3 . 0.5 μl stock of each compound
(1 mM DMSO stock) was transferred to a 96-well PCR plate for screening. In the primary screening, 5 ng NAMPT in 20 μl reaction buffer [0.4 mM phosphoribosylpyrophosphate (PRPP, Sigma), 2 mM ATP, 0.02% BSA, 2 mM DTT, 12 mM MgCl 2 and 50 mM Tris-HCl (pH = 7.5)] was added into each well, the plate was incubated at 37°C for 5 min, then 4.5 μl substrate of NAM was added to initiate the enzyme reaction, resulting in a final concentration of 2% DMSO, 2 μg/ml NAMPT, 0.2 μM NAM and 20 μM compound. After reacting at 37°C for 15 min, the enzyme reaction was terminated by heating at 95 °C for 1 min and cooling in an ice bath. The product of NMN was detected through the following approach: after adding 10 μl 20% acetophenone in DMSO and 10 μl 2 M KOH into each well, the mixture was vortex-mixed and kept in ice bath for 2 min. Then 45 μl 88% formic acid was added and the mixture was incubated at 37°C for 10 min. Finally, 85 μl mixtures in each well were transferred into a flat-bottom 96-well black plate (Greiner), and the fluorescence (F) was measured using a Tecan Infinity M200 plate reader (Tecan Group Ltd.) by setting the excitation and emission wavelength to 382 nm and 445nm respectively. The last row of each 96-well plate includes six wells of background controls and six wells of reference controls.
The relative enzyme activity (Activity%) regulated by specific compound was calculated according to equation (1):
F 0 was the averaged fluorescence of six background controls, representing zero activity from a simulated enzyme reaction with only NAMPT but no NAM and compound; F 100% was the averaged fluorescence of six reference controls, representing 100% activity from intact enzyme reaction without compound perturbation.
Compounds with Activity% less than 40% were considered as inhibitors and subjected to a secondary screen inhibition validation, in which another background control (F C0 ), a simulated enzyme reaction with NAMPT and compound but no NAM, was introduced to eliminate the direct and/or indirect influence from compound. At this stage, the Activity% was calculated according to equation (2):
In the screening, the signal-to-noise (S/N) ratio was calculated using the equation 
NAD measurement
Cellular level of NAD was measured by spectrophotometric enzymatic cycling assay, as described previously [6] [7] [8] 
Sulforhodamine B protein staining (SRB) assay
Cell proliferation was evaluated by sulforhodamine B protein staining (SRB) assay [10] [11] [12] .
Briefly, cells were seeded into 96-well plates, cultured overnight, and treated with corresponding compounds for 72 h. Cells were then fixed with 10% trichloroacetic acid and stained with sulforhodamine B (Sigma). Sulforhodamine B in the cells was dissolved in 10 mmol/L Tris-HCl and was measured at 515 nm using a multiwell spectrophotometer (VERSAmax, Molecular Devices, Sunnyvale, CA). The inhibition rate on cell proliferation was calculated for each well as (A515 control cells -A515 treated cells )/A515 control cells ×100% (A515:
OD value at 515 nm). The average IC 50 values were determined by Logit method from at least three independent tests.
Cell culture and in vitro experiments
Human atmosphere of 95% air plus 5% CO 2 at 37 ℃, as our previously reported 8, 13 .
Isothermal titration calorimetry (ITC)
Thermodynamic parameters of small molecule binding to protein were determined using a
MicroCal VP-ITC calorimeter 14 . NMNAT protein solutions were ultrafiltrated in Amicon Ultra-0.5 Centrifugal Filter Unit (Merck Millipore) against buffer [20 mM Tris (pH 7.5), 20
mM NaCl], which was subsequently used to prepare a matched compound solution. ITC data collected for MS0 were acquired in 5% DMSO to improve compound solubility. Each isotherm was recorded by injecting 554 μM MS0 into 25 μM solutions of protein.
Measurements were performed at 25°C with spacing of 90 s between injections. Background signal (calculated as a mean value) generated by addition of MS0 to buffer was subtracted prior to analysis on Origin 7.5 using software supplied by the manufacturer.
Cellular thermal shift assay (CETSA)
CESTA was performed as previously described 15 In the intact cell experiments, treated cells were exposed to a drug for 3 h in cell culture incubator (95% O 2 and 5% CO 2 ). Control cells were incubated with an equal volume of diluent for the corresponding drug. MS0, MS1, MS7 and MS34 were added from DMSO stocks to the final concentration of 10 μM and DMSO concentration 0.1% except those in ITDRF CESTA . Following the incubation the cells were harvested using Trypsin/EDTA solution and washed with PBS in order to remove excess drug. Equal amounts of cell suspensions were aliquoted into 0.2 mL PCR microtubes, and excess PBS was removed by centrifugation to leave 10 uL or less PBS in each microtube. These cell pellets were heated as previously described and lysed using 2 cycles of freeze-thawing with liquid nitrogen. The soluble fractions were isolated and analyzed by Western blot analysis as described above.
SDS-PAGE and Western blot analysis
Target proteins in CESTA were examined by SDS-PAGE and immunoblotting as previously described 8, 13, 15, 16 . The primary antibodies for Western blotting were specific for the following:
NAMPT (Santa Cruz, sc-67020, used at 1:500), HDAC1 (Cell Signaling, 5356, used at 1:300), and HDAC3 (Cell Signaling, 3949, used at 1:300). To determine the effect of MS0, MS1, MS7 and MS34 on acetylation of histone H3 at Lys9 and Lys18, total cellular and nuclear proteins were extracted according to the instructions of the nuclear and cytoplasmic protein extraction kit (Beyotime, Haimen, China). The protein content of the nuclear extracts was estimated using an enhanced BCA protein assay kit (according to the manufacturer's instructions). Fifty micrograms of protein from each sample were subjected to SDS-PAGE.
The nuclear extracts were separated by SDS-PAGE. The primary antibodies used were:
anti-H3K9 (Cell Signaling, 9753, used at 1:3000), anti-H3K18 (Cell Signaling, 9759, used at 1:3000), and anti-H3-total (Abcam, ab1791, used at 1:3000). Secondary antibodies were
IRDye800CW goat anti-rabbit IgG and IRDye700CW goat anti-mouse IgG (LI-COR
Biosciences, Nebraska, USA). The images were captured and analyzed by the Odyssey infrared fluorescence imaging system (Li-Cor Bioscience). Each experiment was repeated at least three times.
Binding mode study of MS0 with NAMPT AutoDock_Vina1.1.2 program was used to build the binding mode of MS0 with NAMPT.
The 3D-structure of MS0 was modeled and energy-minimized in Chem3D program, and the coordinates of NAMPT (PDBID: 2GVJ) were retrieved from the Protein Data Bank website.
Both structures of MS0 and NAMPT were pre-processed in AutoDockTools1.5.4 17 , such as merge non-polar hydrogens, add Gasteiger charges, set rotatable bond for MS0, add solvation parameter, and so on. The docking space of 15 × 15 × 30Å 3 was visually set around the binding site of FK866, the parameter of exhaustiveness, num modes and energy range was set to 20, 1000 and 5 respectively, and the default values were used for the other parameters. were performed on an API-3000 LC-MS spectrometer. TLC analysis was carried out on silica gel plates GF254 (QindaoHaiyang Chemical, China). Silica gel column chromatography was performed with Silica gel 60 G (QindaoHaiyang Chemical, China). Commercial solvents were used without any pretreatment.
Statistical analysis

tert-butyl
4-((4-(3-(pyridin-3-ylmethyl)thioureido)phenyl)sulfonyl)piperazine-1-carboxylate (MS1).
A solution of sodium bicarbonate (0.17 g, 2 mmol) in water (20 mL) was stirred for 10 min The synthetic method for target compounds MS0, MS3-6, MS8-11, MS15, MS46 was similar to the synthesis of compound MS1.
1-(4-(piperazin-1-ylsulfonyl)phenyl)-3-(pyridin-3-ylmethyl)thiourea (MS2). A solution of
MS1 (0.10 g, 0.2mmol) in CH 2 Cl 2 /TFA (2:1, 10 mL) was stirred at room temperature for 1 h.
The solvent was removed under reduced pressure and the residue was diluted with saturated sodium bicarbonate (50 mL) and then extracted with EtOAc (3× 50 mL). The combined organic layers were washed with saturated sodium chloride solution (3 ×50mL), dried over 
1-(4-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-3-(pyridin-3-ylmethyl)thiourea (MS4).
White solid (0.18 g, yield 45% 
1-(4-((4-acetylpiperazin-1-yl)sulfonyl)phenyl)-3-(pyridin-3-ylmethyl)thiourea (MS5).
White solid(0.14 g, yield 33% The synthetic method for target compounds MS22-37, MS39-45 was similar to the synthesis of compound MS7. (2-methylbenzyl)piperazin-1-yl) (naphthalen-2-ylmethyl)piperazin-1-yl) 
1-(4-((4-(pyridin-2-yl)piperazin-1-yl)sulfonyl)phenyl)-3-(pyridin-3-ylmethyl)thiourea (MS6
1-(4-((4-benzylpiperazin-1-yl)sulfonyl)phenyl)-3-(pyridin-3-ylmethyl)thiourea (MS7
1-(4-((4-cyclohexylpiperazin-1-yl)sulfonyl)phenyl)-3-(pyridin-3-ylmethyl)thiourea (MS8
1-(pyridin-3-ylmethyl)-3-(4-(pyrrolidin-1-ylsulfonyl)phenyl)thiourea (MS9
N-benzyl-4-(3-(pyridin-3-ylmethyl)thioureido)benzenesulfonamide (MS10
1-(4-(morpholinosulfonyl)phenyl)-3-(pyridin-3-ylmethyl)thiourea (MS11
1-(4-((4-(4-fluorobenzyl)piperazin-1-yl)sulfonyl)phenyl)-3-(pyridin-3-ylmethyl)thiourea (MS22
1-(4-((4-
(
1-(4-((4-(3-fluorobenzyl)piperazin-1-yl)sulfonyl)phenyl)-3-(pyridin-3-ylmethyl)thiourea (MS24
1-(4-((4-(2-fluorobenzyl)piperazin-1-yl)sulfonyl)phenyl)-3-(pyridin-3-ylmethyl)thiourea (MS25
1-(4-((4-(4-methylbenzyl)piperazin-1-yl)sulfonyl)phenyl)-3-(pyridin-3-ylmethyl)thiourea (MS26
1-(4-((4-
1-(4-((4-(3-methylbenzyl)piperazin-1-yl)sulfonyl)phenyl)-3-(pyridin-3-ylmethyl)thiourea (MS28
1-(4-((4-(3-chlorobenzyl)piperazin-1-yl)sulfonyl)phenyl)-3-(pyridin-3-ylmethyl)thiourea (MS29)
.
1-(4-((4-(4-bromobenzyl)piperazin-1-yl)sulfonyl)phenyl)-3-(pyridin-3-ylmethyl)thiourea (MS32
1-(4-((4-
1-(pyridin-3-ylmethyl)-3-(4-((4-(4-(trifluoromethoxy)benzyl)piperazin-1-yl)sulfonyl)phe nyl)thiourea (MS35).
White solid (0.067 g, yield 47%). 
1-(4-((4-(4-aminobenzyl)piperazin-1-yl)sulfonyl)phenyl)-3-(pyridin-3-ylmethyl)thiourea (MS38).10%
Pd/C (0.01 g) was added to a stirring solution of MS37 (50mg, 0.1mmol) in EtOAc (10 mL), and the reaction mixture was stirred under hydrogen atmosphere for 12 h at room temperature. The mixture was diluted with water (50 mL) and then extracted with EtOAc (3× 50 mL). The combinedorganic layers were washed with saturated sodium chloride solution (3 ×50mL), dried over anhydrous Na 2 SO 4 and concentratedunder reduced pressure.
The residue was purified by silica gel column chromatography (gradient CH 2 Cl 2 : MeOH = 100:1 to 100:3) to give compoundMS38 as a white solid (34 mg, yield 72%). 
1-(4-((4-((1H
-
1-(4-((4-(furan-2-ylmethyl)piperazin-1-yl)sulfonyl)phenyl)-3-(pyridin-3-ylmethyl)thiour ea (MS42
1-(pyridin-3-ylmethyl)-3-(4-((4-(pyridin-3-ylmethyl)piperazin-1-yl)sulfonyl)phenyl)thio urea (MS45
1-(pyridin-3-ylmethyl)-3-(4-((4-(p-tolyl)piperazin-1-yl)sulfonyl)phenyl)thiourea (MS46).
White solid (0.25 g, yield 51% The synthetic method for target compounds MS14 was similar to the synthesis of compound MS13. The synthetic method for target compounds MS17 was similar to the synthesis of compound 
1-(4-(piperidin-1-ylsulfonyl)phenyl)-3-(pyridin-3-ylmethyl)urea (MS14
1-(4-(piperidin-1-ylsulfonyl)phenyl)-3-(pyridin-3-ylmethyl)guanidine (MS18).
To a stirred solution of 735 (30mg, 0.077mmol) and NaIO 4 (20 mg, 0.09 mmol) in DMF (3 mL), ammonia solution (3 mL) was added and stirred for 6h at 70℃. The mixture was diluted with water (10 mL) and then extracted with CH 2 Cl 2 (3×20 mL). The combined organic layers were washed with saturated sodium chloride solution (3 ×20mL), dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (gradient CH 2 Cl 2 : MeOH = 100:1, 100:2) to give compound MS18 as a white solid (20 mg, yield 71%). The synthetic method for target compounds MS19 was similar to the synthesis of compound 
2-Cyano-1-(pyridin-3-ylmethyl)-3-(4-(pyrrolidin-1-ylsulfonyl)phenyl)guanidine (MS21).
A solution of compound MS9 (0.1 g, 0.26mmol), EDC (0.1 g, 0.55mmol), Et 3 N (0.37 mL) and cyanamide (0.22 g, 5.2 mmol) in THF (20 mL) was stirred at 50℃ for 12 h. Then, the solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography (gradient CH 2 Cl 2 : MeOH = 100:1 to 100:10)to afford compound MS21 as a white solid (0.04g, yield 40% 
